Volume 25, Number 2—February 2019
Online Report
Public Health–Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union
Adoración Navarro-Torné
, Finnian Hanrahan, Barbara Kerstiëns, Pilar Aguar, and Line Matthiessen
, Finnian Hanrahan, Barbara Kerstiëns, Pilar Aguar, and Line Matthiessen
Table 3
Opportunities in the development of the next-generation influenza vaccines
| Opportunity |
|---|
| Faster manufacturing process |
| Continuous production: improving supply and stockpiling |
| Technology transfer to meet the implementation demand |
| Needle-free delivery systems |
| Lower implementation costs (doses, regimen, delivery) |
| Enhanced effectiveness in the elderly |
| Better uptake of the vaccine |
| Expanding influenza vaccine coverage in resource-poor settings |
| Indirect and generalized effects of the vaccine |
| Better arguments for advocacy and education of healthcare professionals and general public |
| Influenza pandemic preparedness planning |
| Age-personalized approach to vaccine development |
| Facilitating pandemic preparedness and response |
| One Health approach |
Page created: January 18, 2019
Page updated: January 18, 2019
Page reviewed: January 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.